Lipolysis today - "Dr. Franz" reviews the current status of research
The Medical Director of the NETWORK, MR Dr. Franz Hasengschwandtner, reviews the current status of research...
Medical Director of the NETWORK, MR Dr. Franz Hasengschwandtner,
reviews the current status of research...|
As a therapy, injection lipolysis (IL) has developed
enormously since 2003 thanks to the activities of our members and the
work of several universities.
This review has the aim of
briefly summarizing the current state of the art.
protocol developed by NETWORK-Lipolysis has been
list of contra-indications has been adjusted each year in line with the
latest insights; the patient anamnesis form is now in Version 8.
list of indications is acquiring clearer form,
thanks also to the feedback from our members. Today, we can describe
the indications for liploysis as follows:
indications that produce particularly good results:
indications with variable results:
- Nasolabial groove
- Axillary folds
- Saddle Bags
- Upper arms
- Pseudogynaecomasty (lipomasty)
- Skin tautening
NETWORK maintains a hotline for dealing with urgent questions and also
a complications management system, even through our rate of
complications is very low (0.00175%).
- 3 publications on the issue of safety based on
retrospective studies by NETWORK members and by the NETWORK itself have
already been published. A further publication is currently in
- The compound developed by the NETWORK has proved
its efficacy. The side-effects have been reduced.
A total of 12
publications have appeared in prestigious medical journals in the
course of the last 3 years. An updated list of the publications is
available at the following link.
the topic of lipoma, a team at Bochum University around senior
physician Dr. Hoffmann and Dr. Falk Bechara has already produced 2
publications; a 3rd publication is due to appear in the near future.
- It should be noted at this point that there is 1
study published by Prof. Daisy Kopera of Graz which comes to the
conclusion that lipolysis does not work. Both at the NETWORK and in
university circles there are serious doubts concerning this study – not
because the outcome doesn’t suit us but because in our opinion the
study design was such that it would inevitably produce redundant
- In contrast to this, an as yet unpublished study by
Prof. Schuller-Petrovich of Vienna states that the active substances,
polyenylphosphatidylcholin (PPC) and desoxycholic acid (DOC), massively
all the cells. Also in the case of this study, we suspect that the
design does not meet the necessary standards. However, it will only be
possible to say more once the study has been published.
- In an animal study involving New Zealand rabbits,
S.Klein, L. Prantl et al. of Regensburg University have demonstrated
that Lipostabil can reduce fat. The results of the study have already
been published. (Note: PPC and DOC are the correct
chemical abbreviatians, PC and DC are often used in literature and in
- In cooperation with the Institute for
Pharmaceutical Technology (Dr. T. Blunk, A.Seitz), S.Klein, L.Prantl et
al investigated both the individual substances and the combination of
active substances contained in Lipostabil on live fat cells in vitro.
The study is already completed, and a publication with the results has
been submitted. Without wishing to anticipate the results, it can be
stated that for the first time they furnish evidence-based proof of
study on the subject of cellulite by Prof. Nor El-Din of Cairo
University is currently in progress. The goal of the study is to
further improve the results of the IL 3-step therapy through
- Already completed and due
for publication in the near future is a study by Prof. Hanan Elkahki of
Shams University in Egypt on the topic of skin tautening using IL
- 2 further studies have not yet started but have
either been already approved by the Ethics Commissions or are due for
assessment by the responsible Ethics Commission. One, under Prof. Roy
de Vita of Rome University, relates to the treatment of buffalo hump in
HIV patients, the other, conducted by Regensburg University under the
leadership of Dr. Lukas Prantl, investigates the treatment of smaller
cushions of fat in vivo.
- Summary of
the current state of the art
evidence, we can state today that the cell membrane of adipocytes is
destroyed by certain substances and substance combinations; we can also
state what those substances are. It should, however, be noted that by
no means all of the processes that take place have already undergone
evidence-based analysis. We can see this from the feedback of our
members concerning unusual results. These take the form of questions on
specific results to which we are not yet able to provide answers. I
would like to present these open questions at this point, also as a way
of showing that a great deal of work still awaits the NETWORK and its
members and that there are still many mysteries waiting to be
the cell membrane is dissolved, why do different patients respond at
different speeds – some already after only 1 treatment, others only
after 2-5? If no reduction in volume can be determined after the 1st
treatment, is this because the fat that has been released simply stays
put in the region until a certain limit (dosage?) is exceeded that
triggers the impulse for the loose fat to be transported away. The
question also arises concerning the extent to which the substances
employed, as well as destroying the membrane, also have an influence on
removal of the fat through detergent effects.
- Sensitivity to pain varies from patient to patient.
Nevertheless, the pain must be kept within a certain limit that the
patient is well able to tolerate. In a very small number of patients,
however, this limit is exceeded, and we have to ask ourselves why that
is the case and what we can do to prevent it.
- A further issue is the non-responder rate. Our goal
must be to reduce this figure to a minimum. To this end, we need
unequivocal answers to the question as to what factors are responsible
for non-response: the experience of the treating physician, the choice
of patient, mental or physiological factors, diagnosis and anamnesis,
consistency of the fat, or simply the number of treatments given, i.e.
whether these patients really are non-responders or “simply” therapy
- The process of metabolization is also theoretically
understood, but so far there have been no enzymatic studies on the
process whatsoever. Such studies could also shed further light on many
of the questions raised here.
- The search for new combinations of active
substances is in full swing. We firmly believe that although the
results are already very good, they could be improved still further,
either through reduction in the side-effects or through enhanced
- To what extent the treatment intervals could be
shortened through combination therapies is also a subject of discussion
within the NETWORK.
Trainings & Workshops:
(click on image)
+49 -2508-21 59-200
Please visit our
Congress Lectures by NETWORK Members
Canada: CACS 5th Annual Congress
Short information about the congress
October 24/25/26, 2008
Montefiore Club, 1195 Guy, Montreal, QUE
Topics: Esthetic medicine & surgery
Lipolysis - Lasers - Fillers
Botox - Fat transfer - Breast - Facelifts - etc.
NETWORK director Dr. Franz Hasengschwandt-
ner will present a lecture about IL - State of the Art.
Link to the programme
AAM & MEDISPA MIDDLE EAST
1st ICAAM & MEDISPA MIDDLE EAST
Intern. Congress in Aesthetic and Anti-aging Medicine & MediSpa
Dubai, UAE - Nov 29 to Dec 1, 2008
This Conference will discuss the latest cutting edge treatments for “Patient’s Global Management”, in the combination of aesthetic and anti-aging medicine.
NETWORK member Dr. Angelo-Khattar will give a lecture about Injection Lipolysis.
NETWORK members Dr. Ines Verner, (Israel) and Mark Palmer (UK) after their lectures on Peels and Injection Lipolysis at the "Interventional Cosmetics" Conference of The Royal Society of Medicine, London, Feb. 25th, 2008. Co-Founder of NETWORK-Lipolysis Ulrich Bunzek (GER) welcomed both at the NETWORK Information booth.